- $54.51m
- $51.55m
- CA$15.56m
Immunoprecise Antibodies Ltd reports results for the quarter ended in April - Earnings Summary
Immunoprecise Antibodies Ltd expected to post a loss of 11 cents a share - Earnings Preview
Brief: Immunoprecise Antibodies Says To Reschedule Financial Results And Recent Business Highlights Report To July 29
Immunoprecise Antibodies Ltd expected to post a loss of 11 cents a share - Earnings Preview
Immunoprecise Antibodies Ltd expected to post a loss of 11 cents a share - Earnings Preview
Brief: Immunoprecise Appoints Kristin Taylor As Chief Financial Officer
Brief: Ipa’S Subsidiary Biostrand And Pgxai Announce Strategic Collaboration
Brief: Ipa Acquires The Carterra Lsa Instrument To Enhance Antibody Discovery And Bolster Its Ai Developments
Immunoprecise Antibodies Ltd reports results for the quarter ended in January - Earnings Summary
Immunoprecise Antibodies Ltd expected to post a loss of 10 cents a share - Earnings Preview
Brief: Immunoprecise Antibodies Ltd Entered Into Sales Agreement Relating To Sale Of Common Shares Offered By The Prospectus Supplement
Immunoprecise Antibodies Ltd reports results for the quarter ended in October - Earnings Summary
Brief: IPA Reports Results and Business Highlights for Q2 FY 2024
Immunoprecise Antibodies Ltd expected to post a loss of 13 cents a share - Earnings Preview
Brief: Ipa Announces Pricing Of $1.1 Million Public Offering Of Common Shares
Brief: Immunoprecise Antibodies - Mitch Levine Has Been Appointed As Chairman Of The Board
Brief: Immunoprecise Antibodies Provides Update On Growth Strategy And Recent Share Price Movement
Brief: Immunoprecise Antibodies Announces CFO Transition
Immunoprecise Antibodies Ltd reports results for the quarter ended in July - Earnings Summary